Names are not evidence.
Approval is product-specific.

An ingredient in prescription GLP-1 medications. Approved brands have specific indications and labeling. A vitamin blend or unapproved freeze-dried preparation is not interchangeable with those approved products.

Compounded semaglutide is not FDA-approved. Adding B6 or B12 does not establish greater benefit or bypass restrictions on compounding copies.

An ingredient in prescription GIP/GLP-1 medications. Product indications differ. Vitamin blends and unapproved freeze-dried preparations must not be described as FDA-approved.

Compounded tirzepatide is not FDA-approved. A prescription alone does not establish that a particular compounded formulation meets federal and state requirements.

Egrifta WR is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight-loss management.

Risks include elevated IGF-1 and blood glucose, swelling and allergic reactions. Contraindications include pregnancy and active cancer. Independently sourced vials and combination blends are not Egrifta WR.

Vyleesi treats acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Approval of Vyleesi does not extend to an independently sourced PT-141 vial.

Not an approved sexual-performance enhancer or treatment for men. Risks include nausea, blood-pressure increases and skin darkening. Contraindicated with uncontrolled hypertension or known cardiovascular disease.

Forzinity received accelerated FDA approval in 2025 to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. That is a specific rare-disease indication.

An independently sourced SS-31 vial is not the approved Forzinity product. Approval does not establish anti-aging or general energy benefits.

An investigational compound. FDA states that retatrutide cannot be used in compounding under federal law.

Not presented as an available prescription treatment, purchase option or alternative to approved medication.

An investigational compound. FDA states that cagrilintide cannot be used in compounding under federal law.

A supplier listing does not establish lawful patient access or FDA approval.

FDA identifies limited safety information and potential immune reactions.

No healing, injury-repair or gut-treatment claims are made here.

FDA identifies safety concerns for both ingredients, including reported serious events.

A combination of these ingredients is not established as an approved hormone or recovery treatment.

FDA notes limited human safety data and potential immune reactions.

Topical-product discussions cannot establish safety or benefit for injectable formulations.

FDA identifies insufficient human safety information for the thymosin beta-4 fragment.

No tendon, muscle or injury-healing promises are made here.

FDA identifies a lack of human exposure data and potential immune reactions.

Not offered here for weight loss, energy or metabolic improvement.

FDA lacks adequate safety information for proposed administration routes.

No lifespan-extension or anti-aging claims are made here.

FDA identifies a potential heart-failure risk in certain patients.

This is not a peptide. Being marketed alongside peptides does not establish approval or safety.

FDA identifies a lack of human exposure and safety data.

Not presented as an established inflammation or digestive treatment.

FDA notes published reports of serious adverse events.

Not presented as a safe tanning or cosmetic injection.

FDA identifies inadequate safety information and potential immune reactions.

No anxiety-treatment or cognitive-benefit claims are made here.

FDA identifies inadequate safety information for the proposed compounded drug.

Not presented as an established immune-boosting treatment.

Marketing names used for combinations of BPC-157, TB-500, GHK-Cu and, for Klow, KPV. A blend name is not an FDA approval or clinical indication.

Safety concerns for the ingredients remain relevant. Combining them does not establish safety, efficacy or lawful compounding.

A combination distinct from tesamorelin alone. Egrifta approval does not extend to this blend.

Ipamorelin safety concerns and formulation-specific regulatory requirements need review.

A growth-hormone-releasing peptide. Independently prepared liquid or freeze-dried formulations should not be described as FDA-approved products.

Historical approval of a different product does not validate these formulations or adult anti-aging claims.

A tripeptide. The ingredient name or preparation format alone is not evidence of product approval, sterility or clinical benefit.

No detox, skin-lightening or immune-boosting promises are made here.

A coenzyme, not a peptide. A vial listing does not demonstrate benefit for fatigue, longevity or general wellness.

Identity, sourcing, preparation quality and the rationale for administration require clinical and pharmacy review.

A nutrient combination, not a peptide. A nutrient combination is not established as an approved weight-loss product.

No fat-burning, detox or guaranteed weight-loss claims are made here.

Research-associated names. Exact identity, formulation and regulatory status are not established by an abbreviated marketing name.

No patient treatment or purchase offer is made for these entries. FOXO4 alone does not identify a specific peptide formulation.